| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 3.070 | 17.022 | 22.693 | 31.990 | 52.992 | 55.460 | 50.490 | 59.480 | 52.651 | 53.119 |
| Total Income - EUR | 3.070 | 19.248 | 22.693 | 32.252 | 53.210 | 55.473 | 50.489 | 59.480 | 52.651 | 53.119 |
| Total Expenses - EUR | 5.876 | 18.172 | 21.700 | 28.089 | 45.217 | 49.137 | 44.888 | 51.562 | 42.903 | 42.029 |
| Gross Profit/Loss - EUR | -2.805 | 1.076 | 993 | 4.163 | 7.993 | 6.336 | 5.600 | 7.918 | 9.749 | 11.090 |
| Net Profit/Loss - EUR | -2.897 | 675 | 426 | 3.207 | 6.893 | 5.852 | 4.372 | 6.401 | 8.384 | 9.577 |
| Employees | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Nikroxgyn Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.206 |
| Current Assets | 11.771 | 21.900 | 49.114 | 50.980 | 32.743 | 39.839 | 49.845 | 47.374 | 41.326 | 45.534 |
| Inventories | 11.668 | 21.405 | 47.927 | 50.582 | 32.164 | 39.395 | 49.456 | 47.027 | 37.501 | 19.507 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 221 |
| Cash | 102 | 495 | 1.187 | 398 | 580 | 444 | 389 | 347 | 3.826 | 25.806 |
| Shareholders Funds | -5.312 | -4.582 | -4.079 | -797 | 6.111 | 11.847 | 15.957 | 22.407 | 30.723 | 40.129 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 17.082 | 26.482 | 53.194 | 51.777 | 26.632 | 27.991 | 33.888 | 24.967 | 10.603 | 6.611 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4719 - 4719" | |||||||||
| CAEN Financial Year |
4719
|
|||||||||
Comments - Nikroxgyn Srl